Releasable PEGylation
Biobetters and prodrugs
Intellectual Property Rights

Biobetters and prodrugs

While established PEGylation methods result in permanent conjugation between the PEG chain and the drug, QuiaPEG’s Uni-Qleaver technology enables the possibility to create

  • new chemical entities in the form of so called “biobetters”, drugs that improve previously approved biological drugs, or
  • prodrugs, i.e. pharmacologically inactive molecules that, after administration, are converted into pharmacologically active drugs.


A biobetter is a biological that has been structurally and/or functionally altered to achieve an improved or a different clinical performance compared to an already approved original (innovator) biological product. Biobetters aim for the same target (e.g. receptor, enzyme) as the innovator product. Alterations used in the design of biobetters usually include chemical modification (e.g. PEGylation) or novel formulation (e.g. novel route of administration, modified release).

Improvements may result in longer half-life (enabling less frequent dosing), better efficacy and/or safety or reduced immunogenicity. Depending on their level of innovation and how well they meet a defined unmet medical need, biobetters may obtain patent and data exclusivity.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message